Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Contineum Therapeutics Q3 2026 Results: Net Loss of $18.7M, Loss Widens

Contineum Therapeutics reported cash and cash equivalents of $75.2 million as of September 30, 2026, compared to $75.6 million at the end of 2025. The company remains in the early stages of clinical development, heavily dependent on its lead candidate PIPE-791 and its collaboration with J&J for PIPE-307.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-18.7-12.8
EPS (diluted, $ a share)$-0.49$-0.45

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: CTNM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Contineum Therapeutics, Inc.: key numbers

Share price
$9.55Close, Nov 17
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Contineum Therapeutics, Inc.

All →
4:09 PM ET 8-K
Financial Results

Contineum Therapeutics Financial Results

Contineum Therapeutics reported third-quarter 2026 financial results, highlighting a net loss of $18.7 million and a cash position of $244.5 million. The company noted that its current capital resources are sufficient to fund operations through mid-2029, providing runway past the estimated completion of its Phase 2 PROPEL-IPF clinical trial. Research and development expenses increased 45% year-over-year to $16.0 million, primarily driven by the PIPE-791 program.

“Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully completed including more than 1,600 patients. We believe the LPAR1 class can be the ideal backbone for combination treatments. Our LPAR1 antagonist, PIPE-791, is potentially differentiated in key ways including a favorable safety and tolerability profile, sustained target engagement which we believe has the potential for improved efficacy, and superior convenience in a one-time daily, low oral dose with no titration required for patients.”

Carmine Stengone, CEO, Contineum Therapeutics

“We continue to expand our footprint for PROPEL-IPF, with over 100 sites now online in 16 countries to facilitate a steady pace of enrollment. With a projected cash runway that extends through mid-2029, we are well positioned with capital resources one year past the estimated completion of our idiopathic pulmonary fibrosis (IPF) trial.”

Carmine Stengone, CEO, Contineum Therapeutics
4:07 PM ET 8-K
Clinical Trial Data

Contineum Therapeutics Clinical Trial Data

Contineum Therapeutics reported that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder did not meet its primary efficacy endpoint of improvement in the MADRS total score. The drug candidate, which is being developed under a global license agreement with Johnson & Johnson, was well-tolerated with no new safety signals. Johnson & Johnson is currently evaluating the full data set, including exploratory endpoints, to determine the next steps for the program.

Counterparty
Johnson & Johnson

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.